Kirsten rat sarcoma viral oncogene homologue (KRAS) is the best-known oncogene with the highest mutation rate among all cancers and is associated with a series of highly fatal cancers, including pancreatic ductal adenocarcinoma (PDAC), nonsmall-cell lung cancer (NSCLC), and colorectal cancer (CRC...
Cancer is the leading cause of death worldwide, and its treatment and outcomes have been dramatically revolutionised by targeted therapies. As the most frequently mutated oncogene, Kirsten rat sarcoma viral oncogene homologue (KRAS) has attracted substantial attention. The understanding ...
2025年2月13日,武汉大学中南医院医学研究院/生命科学学院钟波教授与武汉大学人民医院林丹丹教授课题组合作在Dev Cell上发表了题为KRAS4B oncogenic mutants promote non-small cell lung cancer progression via the interaction of deubiqui...
KRAS 基因突变MUTATION Allele Registry ID:别名: ClinVar ID: 基因突变位点 Ref. Build:GRCh37Ensembl Version:75 Chr.StartStopRef. sVar. Bases 122536236525403737 Transcript ENST00000256078.4 基因序列
KRAS的胚系突变(germline mutation)会影响发育过程中的RAS/MAPK信号传导,引发许多具有类似临床特征的多系统综合征,包括努南综合征(NS)、心-面-皮综合征(CFCS),以及罕见的Costello综合征(CS)。临床中把这一系列发育综合征称为“RASopathies”(RAS信号通路相关综合征),其特点是面部畸形、心脏缺陷、身材矮小和骨骼缺陷...
Huang, L., Guo, Z., Wang, F. et al. KRAS mutation: from undruggable to druggable in cancer. Sig Transduct Target Ther 6, 386 (2021). Hao Wang, Lingling Chi, Fuqiang Yu, Honglin Dai, Chao Gao, Xiaojie Si, Zhengjie Wang, Limin Liu, Jiaxin Zheng, Lihong Shan, Hongmin Liu, Qiurong...
Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial. Nat Med. 2024;30(2):531-542. 6. Jänne PA, Riely GJ, Gadgeel SM, et al. Adagrasib in Non-Small-Cell Lung Cancer Harbori...
RAF1 contributes to cell proliferation and STAT3 activation in colorectal cancer independently of microsatellite and KRAS status Coralie Dorard Claire Madry Manuela Baccarini ArticleOpen Access5 Apr 2023 Oncogene Ras protein abundance correlates with Ras isoform mutation patterns in cancer Fiona E. ...
Mutation rates for KRAS were acquired from the Cancer Facts & Figs. 2000 report published by the American Cancer Society and published articles [26]. CRC, colorectal cancer; LUAD, lung adenocarcinoma; PDAC, pancreatic ductal adenocarcinoma; IDC, invasive ductal carcinoma; STAD, stomach ...
[5]https://www.fda.gov/news-events/press-announcements/fda-approves-first-targeted-therapy-lung-cancer-mutation-previously-considered-resistant-drug [6]https://www.novartis.com/news/media-releases/novartis-announces-early-clinical-data-unique-krasg12c-inhibitor-american-association-cancer-research-annua...